Pharmacokinetics and biodisposition of poly(vinyl alcohol) in rats and mice.
暂无分享,去创建一个
Tetsuro Tanaka | T. Nakano | Y. Kaneo | Tetsuro Tanaka | Takayuki Nakano | Yoshiharu Kaneo | Shiori Hashihama | Atsufumi Kakinoki | Yuka Ikeda | Atsufumi Kakinoki | Yuka Ikeda | Shiori Hashihama
[1] N. L. Krinick,et al. Soluble Polymers as Targetable Drug Carriers , 1991 .
[2] R. Langer,et al. Drug delivery and targeting. , 1998, Nature.
[3] A. Richter,et al. MODIFIED POLYVINYL ALCOHOL‐BENZOPORPHYRIN DERIVATIVE CONJUGATES AS PHOTOTOXIC AGENTS , 1993, Photochemistry and photobiology.
[4] A. Seligman,et al. Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. , 1952, The New England journal of medicine.
[5] J. Kopeček,et al. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. , 1987, Journal of biomedical materials research.
[6] Teruo Okano,et al. Challenges in polymer therapeutics: state of the art and prospects of polymer drugs. , 2003, Advances in experimental medicine and biology.
[7] Tetsuro Tanaka,et al. Evidence for receptor-mediated hepatic uptake of pullulan in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[8] H. Maeda,et al. Evaluation of Poly(vinyl alcohol) for Protein Tailoring: Improvements in Pharmacokinetic Properties of Superoxide Dismutase , 1993 .
[9] J. Kopeček,et al. Soluble synthetic polymers as potential drug carriers , 1984 .
[10] K. Arfors,et al. Stability of fluorescein labeled dextrans in vivo and in vitro. , 1976, Microvascular research.
[11] D. Knook,et al. Fluid endocytosis by rat liver and spleen. Experiments with 125I-labelled poly(vinylpyrrolidone) in vivo. , 1980, The Biochemical journal.
[12] D. Knook,et al. Clearance capacity of rat liver Kupffer, Endothelial, and parenchymal cells. , 1981, Gastroenterology.
[13] S. Kanoh,et al. Polysaccharides as drug carriers: biodisposition of fluorescein-labeled dextrans in mice. , 1997, Biological & pharmaceutical bulletin.
[14] K. Granath,et al. Preparation and properties of fluorescein-labelled dextrans , 1973 .
[15] T. Tanaka,et al. Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. , 2000, International journal of pharmaceutics.
[16] S. Pizzo,et al. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. , 1983, Analytical biochemistry.
[17] F. Greenwood,et al. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.
[18] M T Hearn,et al. 1,1'-Carbonyldiimidazole-mediated immobilization of enzymes and affinity ligands. , 1987, Methods in enzymology.
[19] R. Mehvar,et al. Molecular-weight-dependent pharmacokinetics of fluorescein-labeled dextrans in rats. , 1992, Journal of pharmaceutical sciences.
[20] Y. Ikada,et al. Comparison of Body Distribution of Poly(vinyl alcohol) with Other Water‐soluble Polymers after Intravenous Administration , 1995, The Journal of pharmacy and pharmacology.
[21] Y. Ikada,et al. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[22] R. Duncan. The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.
[23] C. Larsen,et al. High-performance size-exclusion chromatographic procedure for the determination of fluoresceinyl isothiocyanate dextrans of various molecular masses in biological media. , 1989, Journal of Chromatography A.
[24] Hiroshi Maeda,et al. Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.